Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAXEL: Capecitabine 5/7 vs Standard Schedule with Paclitaxel in MBC
NCT00270491Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Dec 2005
- Primary completion
- Oct 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by ARCAGY. Started Dec 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00270491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270491.